Point-of-care biomarkers in asthma management: time to move forward

Kjell Alving; Zuzana Diamant; Sarah Lucas; Helgo Magnussen; Ian D Pavord; Giorgio Piancentini; David Price; Nicolas Roche; Joaquin Sastre; Mike Thomas; Omar Usmani; Leif Bjermer; Respiratory Effectiveness Group, Biomarkers Working Group

doi:10.1111/all.14045

Point-of-care biomarkers in asthma management: time to move forward

Kjell Alving (Corresponding Author), Zuzana Diamant, Sarah Lucas, Helgo Magnussen, Ian D Pavord, Giorgio Piancentini, David Price, Nicolas Roche, Joaquin Sastre, Mike Thomas, Omar Usmani, Leif Bjermer, Respiratory Effectiveness Group, Biomarkers Working Group

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

4 Downloads (Pure)

Abstract

The Global Initiative for Asthma (GINA) report was primarily intended as a strategy document and not a clinical guideline. However, the 2014 update moved the report towards a "practical, clinical practice‐centred document", and has in many countries formed a basis for national guidelines. A possible limitation of the GINA report is its primary focus on evidence coming from randomised controlled trials, potentially leading to the omission of clinically important data coming from real‐life and observational studies, and in conclusions based on highly‐selected asthmatic patients, fulfilling strict study inclusion criteria.

Original language	English
Pages (from-to)	995-997
Number of pages	3
Journal	Allergy
Volume	75
Issue number	4
Early online date	7 Oct 2019
DOIs	https://doi.org/10.1111/all.14045
Publication status	Published - 1 Apr 2020

Keywords

EXHALED NITRIC-OXIDE
PREDICTOR

Access to Document

10.1111/all.14045Licence: Unspecified

Accepted Manuscript
This is the peer reviewed version of the following article: Alving, K., Diamant, Z., Lucas, S., Magnussen, H., Pavord, I.D., Piacentini, G., Price, D., Roche, N., Sastre, J., Thomas, M., Usmani, O., Bjermer, L., and (2020), Point‐of‐care biomarkers in asthma management: Time to move forward. Allergy, 75: 995-997. , which has been published in final form at https://doi.org/10.1111/all.14045. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
Accepted author manuscript, 122 KBLicence: Unspecified

Cite this

@article{1607858d0482425fa4a5e17ef93dbf9e,

title = "Point-of-care biomarkers in asthma management: time to move forward",

abstract = "The Global Initiative for Asthma (GINA) report was primarily intended as a strategy document and not a clinical guideline. However, the 2014 update moved the report towards a {"}practical, clinical practice‐centred document{"}, and has in many countries formed a basis for national guidelines. A possible limitation of the GINA report is its primary focus on evidence coming from randomised controlled trials, potentially leading to the omission of clinically important data coming from real‐life and observational studies, and in conclusions based on highly‐selected asthmatic patients, fulfilling strict study inclusion criteria.",

keywords = "EXHALED NITRIC-OXIDE, PREDICTOR",

author = "Kjell Alving and Zuzana Diamant and Sarah Lucas and Helgo Magnussen and Pavord, {Ian D} and Giorgio Piancentini and David Price and Nicolas Roche and Joaquin Sastre and Mike Thomas and Omar Usmani and Leif Bjermer and {Respiratory Effectiveness Group, Biomarkers Working Group}",

year = "2020",

month = apr,

day = "1",

doi = "10.1111/all.14045",

language = "English",

volume = "75",

pages = "995--997",

journal = "Allergy",

issn = "0105-4538",

publisher = "John Wiley & Sons, Ltd (10.1111)",

number = "4",

}

TY - JOUR

T1 - Point-of-care biomarkers in asthma management

T2 - time to move forward

AU - Alving, Kjell

AU - Diamant, Zuzana

AU - Lucas, Sarah

AU - Magnussen, Helgo

AU - Pavord, Ian D

AU - Piancentini, Giorgio

AU - Price, David

AU - Roche, Nicolas

AU - Sastre, Joaquin

AU - Thomas, Mike

AU - Usmani, Omar

AU - Bjermer, Leif

AU - Respiratory Effectiveness Group, Biomarkers Working Group

PY - 2020/4/1

Y1 - 2020/4/1

N2 - The Global Initiative for Asthma (GINA) report was primarily intended as a strategy document and not a clinical guideline. However, the 2014 update moved the report towards a "practical, clinical practice‐centred document", and has in many countries formed a basis for national guidelines. A possible limitation of the GINA report is its primary focus on evidence coming from randomised controlled trials, potentially leading to the omission of clinically important data coming from real‐life and observational studies, and in conclusions based on highly‐selected asthmatic patients, fulfilling strict study inclusion criteria.

AB - The Global Initiative for Asthma (GINA) report was primarily intended as a strategy document and not a clinical guideline. However, the 2014 update moved the report towards a "practical, clinical practice‐centred document", and has in many countries formed a basis for national guidelines. A possible limitation of the GINA report is its primary focus on evidence coming from randomised controlled trials, potentially leading to the omission of clinically important data coming from real‐life and observational studies, and in conclusions based on highly‐selected asthmatic patients, fulfilling strict study inclusion criteria.

KW - EXHALED NITRIC-OXIDE

KW - PREDICTOR

UR - http://www.mendeley.com/research/pointofcare-biomarkers-asthma-management-time-move-forward

UR - http://www.scopus.com/inward/record.url?scp=85077202709&partnerID=8YFLogxK

U2 - 10.1111/all.14045

DO - 10.1111/all.14045

M3 - Article

C2 - 31505025

VL - 75

SP - 995

EP - 997

JO - Allergy

JF - Allergy

SN - 0105-4538

IS - 4

ER -

Point-of-care biomarkers in asthma management: time to move forward

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this